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Abstract 
Oncological thermal ablation involves the use of hyperthermic temperatures to 
damage and treat solid cancers. Thermal ablation is being investigated as a method 
of treatment in colorectal cancers and has the potential to complement conventional 
anti-cancer treatments in managing local recurrence and metastatic disease. 
Photothermal therapy utilises photosensitive agents to generate local heat and induce 
thermal ablation. There is growing interest in developing nanotechnology platforms to 
deliver such photosensitive agents. An advantage of nanomedicines is their 
multifunctionality with the capability to deliver combinations of chemotherapeutics and 
cancer-imaging agents. To date, there have been no clinical studies evaluating 
photothermal therapy-based nanomedicines in colorectal cancers. This review 
presents the current scope of pre-clinical studies, investigating nanomedicines that 
have been developed for delivering multimodal photothermal therapy to colorectal 
cancers, with an emphasis on potential clinical applications. 
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Introduction 
Colorectal cancer (CRC) is one of the major causes of cancer-related mortalities 
worldwide. There is an increasing trend in CRC incidence, especially in more 
economically developed countries, attributed in part to lifestyle choices such as dietary 
and physical activity patterns 1,2. Surgical intervention remains the cornerstone of CRC 
management with around 80% of new CRC patients presenting with localised disease 
amenable to curative resection 3. Surgery is the first line of treatment, primarily for 
patients with stage I-III CRC. However, up to half of patients diagnosed with early 
stage CRC have recurrent disease after surgical resection and may also develop 
metastatic disease, typically in the liver or lungs 3,4. Patients with metastatic and stage 
IV CRC are usually treated with chemotherapy as the first option, due to the 
unresectable nature of the cancer. If possible, chemotherapy is often used as an 
adjunct to surgery for downstaging or reducing the risk of recurrence. Treatments 
based on 5-fluorouracil, such as FOLFOX (Leucovorin, 5-fluorouracil and Oxaliplatin) 
and FOLFIRI (Leucovorin, 5-fluorouracil and Irinotecan), have been developed for 
patients with metastatic CRC. These treatment regimens have been found to improve 
treatment response, progression-free survival and overall survival rates 5±7. More 
recently, treatment with FOLFOXIRI (Leucovorin, 5-fluorouracil, Oxaliplatin and 
Irinotecan) has been studied and found to be an effective and aggressive approach to 
treat metastatic CRC 8. Targeting biological agents such as Bevacizumab, Cetuximab 
and Panitumumab have also been studied as part of treatment regimens, in 
combination with FOLFOX and FOLFIRI 9±14. Studies on these combination treatment 
regimens, have demonstrated improved treatment response and survival rates in 
patients with metastatic CRC. 
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Despite the benefits of the current chemotherapeutic regimens, a recent review by 
Schuurhuizen et al., highlighted the fundamental limitation of systemic 
chemotherapeutic and biological drugs, that are routinely used to treat late stage and 
metastatic colorectal disease. Whilst these treatment methods increase overall 
survival rates and improve prognosis, systemic toxic effects often have dire 
FRQVHTXHQFHV RQ WKH SDWLHQWV¶ TXDOLW\ RI OLIH 15. In current clinical practice, there 
remains a need for novel treatment methods, which can improve survival rates whilst 
minimising life-affecting adverse toxicities. 
 
Thermal ablation and laser-induced thermotherapy are treatment methods, that may 
be able to address this unmet clinical need 16. These treatments utilise hyperthermia 
to eradicate cancers and have recently been evaluated for treatment of metastatic 
CRC 17. Clinical studies are currently being performed to evaluate the safety and 
efficacy of such treatment strategies 18,19. Similar to the heat-mediated cytotoxicity 
observed in thermal ablation, Photothermal Therapy (PTT) is a non-invasive technique 
which involves the administration of a photosensitive agent, which can convert 
photonic energy into heat upon light irradiation 20. With absorption of photonic energy 
from light, ground state electrons are elevated to an excited energy state. The excited 
electrons then relax and the released kinetic energy overheats the local environment, 
resulting in cell and tissue damage 21. Hyperthermia can induce cell death through 
apoptosis, necrosis and necroptosis (programmed necrosis) 22,23. Intracellular 
temperatures between 40°C to 47°C cause irreversible damage to  cellular proteins 
and impair DNA function, often resulting in apoptotic cell death. In PTT, it is common 
for the intracellular temperature of cancer cells to reach 50°C, resulting in necrosis 
and rapid cell death 22,24. 
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In recent years, there has been much interest in developing new nanomedicines for 
PTT, especially for the treatment of CRC. Nanomedicines and nanoparticle-based 
therapies have advantages over conventional treatments, which are hindered by low 
specificity and poor pharmacokinetics. This has led to the development of various 
nanostructures for biomedicinal applications 21,25. Nanomedicines that can deliver 
combined payloads of chemotherapeutics and cancer-imaging agents are showing 
great promise for potential clinical application 26. This review highlights the pre-clinical 
studies that have evaluated PTT-based nanomedicines as a method of treating and 
managing CRC. To date, no clinical studies have been reported, assessing PTT-
based nanomedicines in CRC patients. 
 
This review is categorised according to the different classes of materials and 
structures, that have been used to develop PTT mediating nanomedicines. The aim of 
this review is to explore the current state of PTT nanotechnologies in pre-clinical 
models of CRC. A summarised overview of all studies included in this review is given 
in Table 1. 
 
Gold-based nanomedicines 
Gold-based nanoparticles (AuNP) are attractive agents for PTT and form the basis of 
many anti-cancer platforms. They are efficient in converting light energy into heat and 
their structural dimensions permit the tailored tuning of AuNP particles to specific 
absorption spectra, including maximum absorption in the near-infrared (NIR) light 
region for optimal tissue penetration. Other benefits of AuNP are good biocompatibility, 
passive accumulation within tumours via the enhanced permeability and retention 
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effect, and the ability to functionalise their surfaces with targeting ligands and 
therapeutic molecules 27,28. AuNP can also be used for optical imaging due to their 
capacity to absorb and scatter light in the visible and NIR regions 29. 
 
2¶1HDOet al. conducted one of the earliest studies of AuNP mediated PTT in CRC.  
The authors coated PEGylated silica nanoshells with gold and evaluated efficacy of 
PTT in vivo in murine CT26 CRC tumour xenografts. Following the intravenous 
injection of gold-coated nanoshells, tumours were irradiated with NIR light. Control 
animals exposed to NIR light only, demonstrated ongoing rapid tumour growth. 
Treated tumours however all showed significant tumour regression and the animals 
appeared healthy and tumour free for more than 90 days post-treatment 30. A 
subsequent study by Goodrich et al. found that CT26 tumour xenograft bearing 
animals treated with PEGylated gold nanorods (AuNR) and NIR irradiation, survived 
for longer than control animals (NIR light irradiation only or AuNR only). AuNR was 
found to selectively accumulate in the tumours and histological analysis confirmed no 
toxicity in vital organs. This study demonstrated the safety and efficacy of AuNR-
mediated PTT in CRC tumours 31.  
 
The versatility of nanomedicines, especially in theranostic applications, has driven 
clinical interest in combining PTT with chemotherapy. Combined treatments have 
previously been described as synergistically improving anti-cancer activity by reducing 
the systemic drug dose and unwanted side effects 32. Guo et al. prepared 
multifunctional nanocarriers based on AuNR and chitosan and loaded them with the 
chemotherapeutic drug, cisplatin. They were able to use the inherent optical properties 
of AuNR to image LoVo CRC cells in vitro in real-time via dark-field optical microscopy. 
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Upon NIR irradiation, no cell death was observed at 1W/cm2 but increasing the light 
output to 3W/cm2 resulted in mass cell death. Cisplatin was found to synergistically 
accentuate the therapeutic effects 33. This study successfully showcased the ability of 
nanoparticles to act as single platforms for drug delivery, cell imaging and PTT. 
 
Kirui et al. conducted a series of experiments, investigating single chain A33-targeting 
antibody functionalised AuNP mediated PTT in CRC 34±36. The cell surface antigen, 
A33, is overexpressed in CRC and may serve as a useful biomarker 37.The authors 
synthesised gold and iron oxide hybrid nanoparticles functionalised with the A33 
antibody. Intracellular accumulation and PTT cytotoxicity following nanoparticle 
administration was significantly increased in SW1222 cells (A33 positive) as compared 
to HT29 cells (A33 negative) CRC cells in vitro. Apoptosis was the primary mode of 
cell death at 5.1W/cm2, with necrosis observed at  higher laser power 36. In a follow 
up study, the authors designed AuNR functionalised with the A33 antibody. Similar to 
their previous study, selective uptake of the functionalised AuNR was observed in 
SW1222 cells and PTT mediated cytotoxicity was only observed in NIR irradiated 
AuNR treated SW1222 cells treated with functionalism AuNR 35. The authors then 
conducted an in vivo analysis using the immuno-functionalised gold and iron oxide 
hybrid nanoparticles. Magnetic resonance (MR) imaging showed selective 
accumulation of the nanoparticle following intravenous injection in SW1222 tumour 
xenografts. PTT treatment of SW1222 CRC xenografts resulted in a reduction in the 
size of tumours. Histopathological examination revealed features of thermonecrosis 
as indicated by the loss of nucleus, cell shrinkage and coagulation in treated 
xenografts with minimal damage in control animals 34. This study demonstrated 
targeted AuNP as an attractive adjunct for image-guided treatment in CRC, combining 
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the optical imaging properties of the nanoparticle with its ability to induce tumour death 
via PTT. 
 
Lee et al. combined chemotherapy and PTT by developing Doxorubicin (DOX) loaded 
AuNP conjugated to anti-death receptor 4 (DR4) antibody. Animals bearing DOX-
resistant DLD1 CRC tumour xenografts were treated with the AuNP and irradiated with 
NIR light. The greatest inhibition in tumour xenografts growth was observed in DR4-
targeted DOX loaded AuNP and PTT treated animals. This was compared to free DOX 
alone, DOX loaded AuNP alone, and AuNP+NIR light treated animals. Combined PTT 
and chemotherapy from a single nanoparticle platform was found to be the most 
effective method of treatment. Packaging DOX into AuNP allowed the 
chemotherapeutic to be retained for longer in the cancer cells. Furthermore, the 
amount of DOX loaded into nanocarriers was 1.8% the amount used in DOX only 
treated animals, showing that lower doses of chemotherapeutics could be effectively 
administered with minimal side effects to treat multidrug resistant tumours 38. 
Hosseinzadeh et al. also investigated combined cancer targeting chemotherapy and 
AuNP mediated PTT. The anti-cancer drug, SN38, was deposited onto the surface of 
AuNP via hyaluronic acid and electrostatic interactions and the AuNP were 
functionalised with MUC1 targeting aptamers. MUC1 positive (HT29 and SW480 CRC 
cell lines) and MUC1 negative (CHO) cell lines were treated with the nanoparticles in 
vitro. Uptake of nanoparticle and subsequent cytotoxicity in HT29 and SW480 cells 
was found to be highest in MUC1 aptamer SN38 loaded AuNP. Again, this was 
compared to free SN38 alone, non-aptamer SN38 loaded AuNP and PTT only treated 
cells. Furthermore, co-treatment of cells with MUC1 aptamer SN38 loaded AuNP and 
light irradiation limited their ability to migrate 39.  
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The ability to combine dual treatments into one nanocarrier and synergise anti-cancer 
effects has been evaluated in Photodynamic Therapy (PDT) and PTT dual therapy. 
Similar to PTT, PDT involves the administration of photosensitising agents, which 
upon excitation, transfer energy to oxygen and superoxides and produce reactive 
oxygen species that cause intracellular oxidative stress and cell death 40. Seo et al. 
developed Methylene blue (MB) loaded AuNR for dual PDT-PTT therapy. CT26 CRC 
cells were treated with MB loaded AuNR and irradiated with NIR light in vitro. 
Cytotoxicity was enhanced in the nanocomposites, as compared to MB-PDT or AuNR-
PTT alone. Interestingly, the NIR light used in this study was remote from the optimal 
absorption wavelength for MB (visible light region). However, the production of 
reactive oxygen species was still enhanced, which may be due to the transfer of 
energy from the excited electrons in AuNR to MB. Similar to previous studies the 
concentration of MB packaged into the nanocomposites was low but still resulted in a 
significant anti-cancer response 41. 
 
The transmembrane protein, Mucin 1 (MUC1), is associated with increased 
proliferation and metastasis in CRC 42. As described above, Hosseinzadeh et al. 
exploited the over expression of MUC1 in CRC to target nanoparticles to MUC1 
positive cells. Similarly, Azhdarzadeh et al. synthesised gold coated 
superparamagnetic iron oxide nanoparticles (SPIONs) functionalised with MUC1 
aptamers. SPIONs are popular theranostic agents, especially for MR imaging, with the 
gold coating conferring biocompatible and photothermal properties 43. MR imaging 
confirmed the uptake of nanoparticles into MUC1 HT29 CRC cells. Upon NIR 
irradiation, nanoparticle treated cells showed significant cell death whilst control cells 
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(nanoparticle only and no light irradiation) remained viable 44. White et al. evaluated 
PTT in anti-Mucin 5B antibody conjugated AuNP in liver metastatic models of CRC. 
Similar to MUC1, the overexpression of Mucin 5B (MUC5B) is associated with 
carcinogenesis and metastasis in gastric and CRC cancers 45. Metastasis was 
modelled by implanting CC531 CRC cells into the liver of rats. Anti-MUC5B conjugated 
AuNP were injected through the tail veins and MR imaging confirmed the selective 
uptake of AuNP into hepatic metastatic deposits. Following light treatment, histological 
analysis confirmed large areas of tumour necrosis induced by PTT. No toxicity was 
observed in any of the major organs 46. Recently, Parchur et al. reported a multimodal 
nanoparticle consisting of a gadolinium oxide shell coated on AuNR. Using a similar 
liver metastasis model, Gadolinium-mediated MR imaging confirmed a significant 
accumulation of AuNR into metastatic deposits. Histopathological analysis confirmed 
thermal damage in the tumour regions following fiber optic delivery of NIR light and 
photothermal ablation, with minimal damage to adjacent liver tissue 47. Pathological 
hypoxia in solid cancers, plays an important role in aiding the progression and 
dissemination of cancer 48. The expression of Carbonic Anhydrase IX (CAIX) is 
upregulated under hypoxic conditions, due to the highly induced activity of Hypoxia-
LQGXFLEOHIDFWRUĮ 49. In CRC cells, CAIX has been shown to promote the invasive 
potential and survival in cells. Plus, CAIX protein expression correlates with poor 
prognosis in solid tumours 50. To exploit the importance of CAIX, Chen et al. developed 
AuNR constructs, conjugated to anti-CAIX antibody. Under hypoxic conditions, the 
binding and uptake of CAIX-targeted AuNR into HT29 CRC cells in vitro was higher, 
in comparison to non-targeted AuNR treated cells. Upon NIR irradiation, CAIX-
targeted AuNR treated cells were found to experience significantly higher cell death, 
in comparison to control AuNR and untreated cells. Hyperspectral imaging in vivo, 
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confirmed a high accumulation of intravenously administered CAIX-targeted AuNR in 
HT29 xenografts, with penetration into the hypoxic areas of the tumours. In vivo NIR 
light irradiation of tumour xenografts, resulted in complete tumour regression in CAIX-
targeted AuNR treated animals. Transient tumour regression followed by recurrence 
was observed in non-targeted AuNR treated animals 51. 
 
The studies described above utilised CRC targeting antibodies and aptamers to direct 
and catalyse AuNP mediated PTT. Wang et al. constructed gold and silver hybrid 
nanorods conjugated to CRC specific phage fusion proteins. Selective uptake into 
SW620 CRC cells was confirmed via electron microscopy, and the gold and silver 
hybrid nanorods were efficient in inducing PTT mediated cell death 52. 
 
 
Dye-based nanomedicines 
NIR dyes are small organic molecules that can absorb light in the NIR region and are 
of interest in anti-cancer theranostic applications. NIR dyes have great versatility and 
can be used in a wide variety of clinical applications. This includes fluorescent imaging, 
PDT, and PTT 53. IR780 is a lipophilic NIR heptamethine cyanine dye which has shown 
great promise in anti-cancer related applications 54. Due to its hydrophobic nature, 
IR780 can be packaged into nanoparticles to improve uptake into cancer cells 54,55. 
Peng et al. developed IR780 loaded micelles for NIR fluorescence and PTT. The 
micelles were also labelled with the radionuclide, rhenium-188 for nuclear imaging. 
HCT116 CRC cells treated with the IR780-micelles and irradiated with NIR exhibited 
significant cell death in vitro, as compared to IR780-micelles treated alone or NIR 
irradiation alone. Animals bearing HCT116 CRC tumour xenografts were fluorescently 
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imaged following the administration of the IR780-micelles and showed a high uptake 
at 96 hours. Following NIR light irradiation, substantial tumour regression was 
observed in animals treated with IR780-micelles as compared to controls. 
Photothermal ablation in treated tumours was confirmed by histopathological analysis, 
which showed large areas of thermonecrosis, irreversible tissue damage, increased 
apoptosis, and increased expression of heat shock proteins 55. Shih et al. took this 
concept one step further by conjugating the EGFR targeting monoclonal antibody, 
Cetuximab, onto IR780 loaded micelles. NIR fluorescence showed high in vitro and in 
vivo uptake of the micelles into HCT116 CRC (high EGFR expression) cells as 
compared to SW620 CRC (low EGFR expression) cells. Following NIR irradiation, all 
HCT116 tumour xenografts treated with Cetuximab conjugated IR780-micellles had 
significant tumour regression. In comparison, SW620 tumour xenografts relapsed after 
13 days 56. 
 
Tsai et al. described a multiplatform and multifunctional nanoparticle composed with 
IR780 and SN38 as the core of the structure. The structure was PEGylated and was 
functionalLVHGZLWK WKHĮYȕ LQWHJULQ WDUJHWLQJSHSWLGHF5*'7KHGXDO IXQFWLRQRI
IR780 enabled non-invasive NIR fluorescent imaging to verify nanoparticle 
accumulation in tumour xenografts and NIR irradiation to generate heat for PTT. 
HCT116 CRC tumour xenografts treated with the nanoparticle and irradiated with NIR 
light exhibited a rapid increase in temperature, reaching 52°C in 60 seconds. 
Combining PTT with SN38 further enhanced tumour regression in a synergistic 
fashion 57. Lin et al. GHVLJQHGDQGHYDOXDWHGµJUHQDGH¶-like nanocages to deliver DOX 
to CRC cells. The nanocage comprised of DOX in the core with the NIR dye, ADS-
780, on the surface. Following the administration of the DOX loaded nanocages to 
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HT29 CRC cells, NIR fluorescent imaging was used to track the uptake of the 
nanocages. Upon NIR light irradiation, cell death and tumour regression was observed 
in vitro and in vivo respectively. The thermal effects of ADS-780 also triggered the 
explosion of nanocages into smaller clusters and the acidic intracellular pH triggered 
the release of DOX from the clusters. NIR light and nanocage treated groups had a 
longer survival with histological analysis showing great anti-cancer effects. There were 
no signs of cytotoxicity in other major organs 58. 
 
Indocyanine green (ICG) is a well-known NIR dye and its inherent fluorescent 
properties, have been utilised in many medical and surgical specialities 59. ICG is also 
a photosensitising agent and can produce reactive oxygen species (ROS), as well as 
heat, upon light irradiation 60. Chen et al. created ICG and DOX loaded nanoparticles 
and took advDQWDJH RI ,&*¶V DELOLW\ WR SURGXFH 526 DQG WULJJHU WKH LQWUDFHOOXODU
release of DOX. HCT116 CRC tumour xenograft treated mice exhibited enhanced 
cytotoxicity and tumour growth regression following treatment with DOX and ICG 
loaded nanoparticle with NIR light irradiation. Thermal imaging confirmed PTT, as 
tumour xenograft temperatures rose to around 50°C following li ght treatment. 
Hyperthermia also aided the increased accumulation of ICG in the tumour 61.  
 
Serendipitously, Chinese traditional ink, a conventional writing material, was found to 
share similar optical and chemical properties as artificially synthesised NIR dyes. 
Wang et al. explored the photothermal effects of Chinese traditional ink in lymph node 
metastatic models of CRC. HCT116 CRC cells were subcutaneously implanted into 
mice and the animals that developed metastases in sentinel lymph nodes were used 
for experiments. Following the administration of the ink and NIR light irradiation, 
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thermal imaging was employed to map the location of the ink with temperatures in the 
sentinel lymph nodes reported to be around 60°C. Several da ys after PTT the lymph 
nodes were histopathologically examined and showed signs of necrosis and pyknosis. 
In contrast, intact morphology of cells with no anti-cancer effects were observed in 
control lymph nodes. Furthermore, Chinese traditional ink was found to be safe and 
biocompatible as indicated by no pathological damage to any of the major organs 62. 
 
Carbon nanotubes-based nanomedicines 
Carbon nanotubes (CNT) have attracted the interests of biomedical researchers due 
to their electrical, thermal and spectroscopic properties. CNT offer a potentially useful 
platform for developing photothermal agents due to their ability to efficiently convert 
NIR light energy into heat 63. Tan et al. developed modified multiwalled CNT by 
functionalising CNT with the nanocomposite, polyhedral oligomeric silsesquioxane 
poly (carbonate-urea) urethane (POSS-PCU). POSS-PCU functionalising plays a 
similar role to PEGylation in that it improves biocompatibility, addresses inherent 
toxicity, and prolongs the degradation of nanomedicines in the systemic circulation 64. 
In this study, the authors treated HT29 CRC cells with the POSS-PCU functionalised 
CNT and irradiated cells with NIR light. There was a 95% reduction in cell viability and 
negligible reduction in cell viability in cell cultures treated with the modified CNT, but 
not irradiated with NIR light 65. Graham et al. also investigated multiwalled CNT by 
conjugating folic acid on to the surfaces. Folate receptor is known to be overexpressed 
in many cancers, including CRC, and has been exploited to target imaging agents and 
therapeutic compounds towards cancerous tissues 66. Following incubation with the 
folic acid functionalised CNT and NIR light irradiation, cytotoxic analysis showed a 
significant reduction in cell viability in HCT116 and RKO CRC cells. Similar to the 
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previous study, no cell death was observed in cells treated with CNT, but not irradiated 
with NIR light 67. Levi-Polyachenko et al. explored the hyperthermia inducing ability of 
CNT to improve the uptake and delivery of oxaliplatin and mitomycin C. The clinical 
relevance for this is its potential use in Hyperthermic Intraperitoneal Chemotherapy to 
treat peritoneal metastasis 68. The authors loaded the chemotherapeutics into 
multiwalled CNT and incubated it with HCT116 and RKO CRC cells. There was a rapid 
accumulation of the chemotherapeutics into cells (tens of seconds), and the 
intracellular amount of anti-cancer drugs was found to be similar to cells incubated 
with the chemotherapeutics for two hours under non-hyperthermic conditions. Cell 
viability analysis showed a synergistic effect on cell death, mediated by combined 
CNT-PTT and oxaliplatin/mitomycin C toxicity 69. 
 
 
Graphene oxide-based nanomedicines 
Graphene is the fundamental building block in graphitic materials, and can be 
fashioned into many different geometrical structures. Graphene, graphene oxide, and 
other derivatives have been extensively explored for theranostic applications in 
nanomedicines due to their low cost, large molecular surface area, chemical and 
mechanical stability, low toxicity and biocompatibility. Graphene also exhibits high 
photonic energy absorption in the NIR range, making it a suitable candidate for PTT 
70,71
. Fiorica et al. developed a hyaluronic acid based nanogel network with graphene 
oxide incorporated into the nano-structure. The anti-cancer drug, irinotecan, was 
loaded into the core of the nano-structure. The authors evaluated the multimodal 
activities of the nanogel in 3D spheroidal co-culture models of CRC comprised of 
HCT116 CRC cells and human dermal fibroblasts. The 3D models were directly 
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injected with the nanogel constructs, mimicking intratumoural injections. The nanogel 
was taken up by HCT116 cells, which may have been due to the recognition of 
hyaluronic acid by overexpressed cancer cell surface markers, such as CD44 72. 
Following NIR light irradiation, the destruction of both HCT116 CRC and healthy 
fibroblasts was observed in irinotecan loaded nanogel treated 3D models. Cytotoxicity 
was observed throughout the 3D model. This contrasted with necrosis alone being 
observed in the light irradiation spot on 3D models treated with non-irinotecan loaded 
nanogels. Viable HCT116 and fibroblasts were still present around the light irradiation 
spot 73. Einafshar et al. used sheets of graphene oxide to produce biocompatible 
nanocarriers of SN38. The nanoparticles were comprised of SPIONs and were 
functionalised with cyclodextrins to improve aqueous solubility and confer 
biocompatibility. HT29 CRC cells were treated with the nanoparticle in vitro, and the 
results indicated a synergistic mode of cell death with combined graphene oxide-PTT 
and SN38-chemotherapy. This study also highlighted the effectiveness of designing 
nano-platforms to be used as dual carriers of chemotherapeutic and PTT agents 74. 
Lu et al. developed a dual-targeting nanoparticle to deliver PTT and chemotherapy to 
CT26 CRC tumour xenografts. Magnetic nanoparticles were deposited on graphene 
oxide, which was then functionalised by PEGylation and Cetuximab was conjugated 
on to the nanoparticles. DOX was then loaded on to the nanoparticles. Magnetic 
guidance was employed to attract the nanoparticle towards the tumour xenografts, 
with Cetuximab binding to cells overexpressing EGFR. The nanoparticles were taken 
up via endocytosis, followed by the intracellular release of DOX. Following intravenous 
injection and application of magnetic field and NIR light irradiation, substantial 
regression in tumour growth was observed in treated animals. In comparison, the other 
animal groups (free DOX alone, DOX loaded nanoparticle alone, DOX loaded 
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nanoparticle + magnet alone) showed an initial regression in tumour growth but 
tumours relapsed after a few days. Histopathological analysis revealed large areas 
necrosis in tumour xenografts from treated animals 75. 
 
Transition metals-based nanomedicines 
The use of transition metals as oxides, hybrid structures, and alloys are being 
evaluated in an effort to create more efficient biofunctional nanomaterials and 
platforms with high photothermal effects 76. Lee et al. reported the use of titanium oxide 
nanotubes (TONT) as mediators of PTT. In comparison to AuNP and CNT, TONT 
absorb more NIR light energy and convert light to heat more efficiently. In vitro 
cytotoxicity analysis found CT26 CRC to respond to TONT treatment and NIR light 
irradiation, with a significant reduction in cell viability. TONT was also found to be non-
toxic when incubated with cells and devoid of NIR light irradiation 77. Liu et al. 
developed a theranostic agent by combining MR imaging and PTT into a single 
nanoparticle. The nanoparticles were assembled using iron (Fe3+), gallic acid and 
poly(vinylpyrrolidone). Due to the small size of the nanoparticles, they were found to 
preferentially accumulate in SW620 CRC tumour xenografts. The intratumoural acidic 
pH enhanced MR imaging and following NIR light irradiation, tumours were completely 
ablated due to the PTT mediating properties of Fe3+ 78. Zhang et al. created a 
multimodal iron based hybrid anisotropic nanoparticle. Cell viability analysis showed 
cytotoxicity in nanoparticle and laser irradiation treated HT29 cells in vitro. Following 
the injection of the iron-nanoparticle into HT29 CRC tumour xenograft bearing animals, 
photoacoustic and MR imaging was used to track the uptake and dissemination of 
nanoparticles. Once the optimal time for intratumoural accumulation was identified, 
NIR light irradiation was applied to the tumour xenografts. Two days after irradiation, 
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tumour sizes in treated mice had regressed significantly. Histopathological analysis of 
tumour sections confirmed high therapeutic efficacy with apparent extensive necrosis 
79
.  
  
In comparison to gold and other inorganic materials, copper is cheap, easily obtainable, 
biocompatible and possesses efficient photothermal properties. This makes it 
advantageous for the mass production of copper-based nanoparticles. Hessel et al. 
developed copper selenide (CuSe) nanocrystals, which exhibited strong NIR optical 
absorption. Cellular destruction was observed following the treatment of HCT116 CRC 
cells in vitro, with CuSe nanocrystals and NIR light irradiation 80. Li et al. investigated 
PEGylated copper nanowires (CuNW) as PTT mediating agents. CuNW was found to 
efficiently generate heat upon NIR light irradiation. In vitro analysis showed CuNW 
intertwining around CT26 CRC cells and upon light irradiation heat was transmitted to 
cells, triggering thermal induced cell ablation. CT26 CRC tumour xenograft bearing 
animals were then injected with CuNW and irradiated with NIR light. Tumoural 
temperatures rose and tumour growth was suppressed. Necrosis was found to be the 
primary mode of cell death, as indicated by release of the damage associated 
molecular pattern molecule, HMGB1 81.  
 
Polymerically structured nanomedicines 
Hong et al. evaluated porous silicon as a PTT mediating agent and found that, in 
combination with NIR light irradiation, CT26 CRC cells experienced substantial 
cytotoxicity in vitro. Porous silicon or NIR light irradiation alone did not influence cell 
viability. In vivo treatment of animal bearing CT26 CRC tumour xenografts with porous 
silicon and NIR light irradiation resulted in tumour regression with the animals 
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remaining healthy and tumour-free for more than 3 months. Furthermore, surrounding 
healthy tissue was found to be free from thermal damage 82. Similarly, MacNeill et al. 
developed a novel chemically modified polymer nanoparticle. The nanoparticle was 
stable and non-toxic under non-NIR light conditions. Upon NIR light irradiation, the 
nanoparticle generated temperatures above 50°C in vitro. Ph otothermal ablation was 
seen in HCT116 and RKO CRC cells treated with the nanoparticle and NIR light 
irradiation 83. Recently, polyaniline-based nanoparticles (PANP) have been developed 
with strong NIR optical absorption properties 84. Zhou et al. investigated PANP and 
found that the cytotoxicity of PANP was dependant on NIR light irradiation in vitro. 
HCT116 CRC tumour xenograft bearing mice were treated with PANP and NIR light 
irradiation. Complete tumour regression was observed 5 days after treatment and 
tumours did not regrow 85.  
 
Ideally, nanomedicines that have been developed for PTT should possess strong 
optical absorption in the NIR range (700nm ± 2000nm, typically 800nm) of the 
electromagnetic spectrum 86. Kelkar et al. developed a dual wavelength absorbing 
nanoparticle for PTT. The nanoparticle could absorb light at 450nm and 800nm. The 
rationale was that the shorter wavelength would be better suited to treat superficial 
lesions, whereas the longer wavelength could penetrate into deeper tumours. In vitro 
cell viability analysis in CT26 CRC cells showed that irradiation at both wavelengths 
resulted in a nanoparticle-dose dependant reduction in cell viability. Simultaneous 
application of both wavelengths was found to be better than blue (450nm) and NIR 
(800nm) wavelengths alone 87. Yang et al. investigated SN38-loaded nanoporphyrin 
micelles. This tri-modal therapeutic platform could impart PTT, PDT and 
chemotherapeutic effects. Under non-light conditions, the micelles were stable, but 
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upon light irradiation they resulted in a controlled release of SN38. In vitro analysis 
showed a dose-dependent uptake and light-dependant reduction in cell viability in 
HT29 CRC cells. Due to the small size of the micelles, they were retained longer in 
tumours, as compared to the major organs in animal models. Complete tumour 
regression was observed in animals bearing HT29 CRC tumour xenografts treated 
with SN38-loaded nanoporphyrin micelles and light. Histopathological analysis 
showed signs of necrosis and pyknosis 88. 
 
Potential clinical applications 
As highlighted in this review, there are many classes, derivatives and highly modified 
multimodal nanomedicines that can deliver PTT to CRC. The studies evaluated in this 
review are pre-clinical in nature, showing great promise. However, there is still a long 
way to go before these techniques can be clinically applied. AuNP are the most 
favoured class of nanoparticles in PTT, due to their many inherent advantages in 
optical imaging, eliciting PTT and serving as effective nanocarriers. AuNP were the 
first class of nanoparticles to be evaluated for PTT in CRC, and are still being studied 
today. In addition, as summarised in Table 1, there are more AuNP-based PTT pre-
clinical studies in CRC, in comparison to other classes of PTT mediating nanoparticles.  
Recently, Stern et al. published the findings of a small scale clinical study, evaluating 
the toxicity of AuNP in patients with prostate cancer. The primary endpoint of this study 
was patient safety, and the clinical safety profile of AuNP was found to be excellent 
and strongly supports further investigation 89. Based upon the pre-clinical findings in 
this review and the aforementioned clinical study, there is ample evidence suggesting 
that AuNP-based PTT nanomedicine is a very attractive method of treatment in CRC, 
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and a strong candidate that would greatly benefit from early phase clinical evaluation 
in the near future 90. 
 
Intraoperative PTT shows great clinical potential, as a treatment option for metastatic 
CRC. As PTT is similar to PDT, there are similarities in the clinical application of both 
treatment methods. In PDT, following the systemic administration of the 
photosensitising agent, light is delivered laparoscopically through optical fibers to the 
site of tumour growth. This method for practising intraoperative PDT, has shown to be 
the optimal and safest route for treating patients 91. Without light mediated activation, 
photosensitising agents are unable to elicit cytotoxicity. It would therefore be practical, 
to employ the same technique for PTT. Due to the flexibility of optical fibres, light 
delivery can be localised and made accessible to any organ, making it ideal for 
precisely targeting metastatic CRC lesions.  
 
Limitations of nanomedicines 
The enhanced permeability and retention (EPR) effect is often described as a potential 
drawback in the clinical application of nanomedicines. Briefly, the EPR effect 
describes the extravasation of intravascular fluids from systemic circulation, carrying 
plasma proteins and macromolecules into the interstitial spaces within the tumour 
microenvironment. This is usually brought on by the leakiness and compromised 
structure of the tumour vasculature 92. Coupled with the ineffective lymphatic filtration 
system in the tumour microenvironment, extravasated macromolecules are prevented 
from being removed back into systemic circulation 93. The EPR effect is the basis on 
which nanomedicines are delivered to the tumour. Paradoxically, a major obstacle to 
this system, is the build-up of colloid osmotic pressure as a result of the EPR effect 94. 
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The continuous extravasation and accumulation of intravascular fluids, can increase 
the interstitial fluid pressure and impede the delivery of nanomedicines. 
 
Off-target effects of non-targeted nanomedicines and challenged pharmacokinetics i.e. 
the inability to penetrate through multiple layers of tissues, can also result in the 
inefficient delivery of nanomedicines and treatment of tumours. There is on-going 
research to potentially improve the delivery of nanomedicines to tumours, which 
includes the use of magnetic nanoparticles, ultrasound and through the exploitation of 
tumour-specific physiology 95. 
 
Conclusion 
This review highlights the pre-clinical evaluations of nanomedicines for PTT in CRC. 
Thermal ablation is an effective method for treating solid cancers and via nanocarriers, 
nanoparticles, and similar platforms, it is possible to directly deliver photothermal 
agents to cancers. As detailed in this review, multimodal PTT-nanomedicines have 
been produced in various forms, which can deliver combinations of cancer-imaging 
agents and chemotherapeutics in addition to the photothermal agent (Figure 1). To 
date, the results are limited to pre-clinical (cancer cell line and tumour xenograft) 
models. Next steps are to investigate PTT-based nanomedicines for CRC, in a clinical 
setting. This would involve setting up phase I small scale pilot or feasibility studies, 
evaluating nanomedicine toxicity, safety of NIR light irradiation and the treatment 
efficacy of PTT-based nanomedicines. These clinical studies can be used to 
investigate this technique as either a stand-alone method of treatment, or combined 
with surgery. These vital studies are necessary, to demonstrate the clinical benefit of 
this technology in human CRC. 
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Figure captions 
 
Figure 1 ± Schematic diagram of a multimodal targeted PTT nanomedicine 
Multimodal nanomedicines combine different therapies such as near-infrared (NIR) 
light absorbing nanoparticles to mediate Photothermal therapy (PTT) and conventional 
chemotherapeutic drugs i.e. Doxorubicin, SN38 and Oxaliplatin. Nanomedicines can 
be functionalised with superparamagnetic iron oxide nanoparticles (SPIONs) to 
facilitate magnetic resonance imaging and polyethylene glycol (PEG) to improve 
biocompatibility and prolong systemic circulation. Cancer-targeting ligands such as 
antibodies, aptamers and hyaluronic acid can be conjugated onto nanomedicines to 
improve the delivery and uptake of nanomedicines in cancers. 
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Table 1. A summary of the studies evaluating photothermal therapy nanomedicines in 
colorectal cancer 
Class of 
nanomedicine Reference 
Pre-clinical model 
of colorectal 
cancer 
Intended application of 
nanomedicine Outcomes of treatment 
Gold Nanoparticles 
2¶1HDO 30 CT26 tumour 
xenografts in vivo PTT 
Tumour growth 
regression  
Goodrich 2010 31 CT26 tumour 
xenografts in vivo PTT 
Treated animals were 
free of tumour growth 
Guo 2010 33 LoVo cells in vitro PTT, cell imaging and deliver Cisplatin 
Synergistic chemo- and 
PTT cytotoxicity 
Kirui 2010 36 SW1222 and HT29 cells in vitro Targeted PTT 
PTT induced 
cytotoxicity 
Kirui 2011 35 SW1222 and HT29 cells in vitro Targeted PTT 
PTT induced 
cytotoxicity 
Kirui 2013 34 
SW1222 and 
HT29 tumour 
xenografts in vivo 
Targeted PTT and 
tumour imaging 
Tumour regression and 
confirmed tissue 
necrosis 
Lee 2014 38 
DLD1 cells in vitro 
and tumour 
xenografts in vivo 
Targeted PTT and 
deliver Doxorubicin 
Synergistic chemo- and 
PTT tumour growth 
regression  
Hosseinzadeh 
2017 39 
HT29 and SW480 
cells in vitro 
Targeted PTT and 
deliver SN38 
Synergistic chemo- and 
PTT cytotoxicity 
Seo 2014 41 CT26 cells in vitro PTT and PDT Synergistic PDT and PTT cytotoxicity 
Azhdarzadeh 
2016 44 HT29 cells in vitro 
Targeted PTT and cell 
imaging 
PTT induced 
cytotoxicity 
White 2017 46 
Liver metastasis 
of orthotopic 
CC531 deposits 
in vivo 
Targeted PTT and 
tumour imaging 
PTT induced confirmed 
tissue necrosis 
Parchur 2018 47 
Liver metastasis 
of orthotopic 
CC531 deposits 
in vivo 
PTT and tumour 
imaging 
PTT induced confirmed 
tissue necrosis 
Chen 2018 51 
HT29 cells in vitro 
and tumour 
xenografts in vivo 
PTT and tumour 
imaging 
PTT induced 
cytotoxicity and 
complete tumour 
regression 
Wang 2014 52  SW620 cells in 
vitro Targeted PTT 
PTT induced 
cytotoxicity 
Dye-based 
nanoparticles 
Peng 2011 55 
HCT116 cells in 
vitro and tumour 
xenografts in vivo 
PTT and tumour 
imaging 
Tumour regression and 
confirmed tissue 
necrosis 
Shih 2017 56  
HCT116 and 
SW620 cells in 
vitro and tumour 
xenografts in vivo 
Targeted PTT Tumour growth 
regression  
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Tsai 2017 57 HCT116 tumour 
xenografts in vivo 
PTT, cell imaging and 
deliver SN38 
Synergistic chemo- and 
PTT tumour growth 
regression  
Lin 2018 58 
HT29 cells in vitro 
and tumour 
xenografts in vivo 
PTT, cell imaging and 
deliver Doxorubicin 
Synergistic chemo- and 
PTT improvement in 
survival 
Chen 2017 61 HCT116 tumour 
xenografts in vivo 
PTT and deliver 
Doxorubicin 
Synergistic chemo- and 
PTT tumour growth 
regression  
Wang 2017 62 
Lymph node 
metastasis of 
HCT116 tumour 
xenografts in vivo 
PTT Necrosis and pyknosis in lymph nodes 
Carbon nanotubes 
Tan 2012 65 HT29 cells in vitro PTT PTT induced 
cytotoxicity 
Graham 2013 67 HCT116 and RKO 
cells in vitro Targeted PTT 
PTT induced 
cytotoxicity 
Levi-Polyachenko 
2009 69 
HCT116 and RKO 
cells in vitro 
PTT and deliver 
Oxaliplatin/Mitomycin C 
Synergistic chemo- and 
PTT cytotoxicity 
Graphene oxide 
nanoparticles 
Fiorica 2017 73 
3D co-culture 
model of HCT116 
CRC cells and 
human dermal 
fibroblasts 
Targeted PTT and 
deliver Irinotecan 
Synergistic chemo- and 
PTT cytotoxicity 
Einafshar 2018 74 HT29 cells in vitro PTT and deliver SN38 Synergistic chemo- and PTT cytotoxicity 
Lu 2018 75 CT26 tumour 
xenografts in vivo 
Targeted PTT and 
deliver Doxorubicin 
Tumour regression and 
confirmed tissue 
necrosis 
Transition metals-
based nanoparticles 
Lee 2010 77 CT26 cells in vitro PTT PTT induced 
cytotoxicity 
Liu 2015 78  SW620 tumour 
xenografts in vivo 
PTT and tumour 
imaging 
Tumour growth 
regression  
Zhang 2016 79 
HT29 cells in vitro 
and tumour 
xenografts in vivo 
PTT and tumour 
imaging 
PTT induced 
cytotoxicity, tumour 
growth regression and 
confirmed tissue 
necrosis 
Hessel 2011 80  HCT116 cells in 
vitro PTT 
PTT induced 
cytotoxicity 
Li 2016 81 
CT26 cells in vitro 
and tumour 
xenografts in vivo 
PTT 
PTT induced 
cytotoxicity and tumour 
growth regression 
Polymerically 
structured 
nanomedicines 
Hong 2011 82 
CT26 cells in vitro 
and tumour 
xenografts in vivo 
PTT 
PTT induced 
cytotoxicity and tumour 
growth regression 
MacNeill 2013 83 HCT116 and RKO 
cells in vitro PTT 
PTT induced 
cytotoxicity 
Zhou 2013 85 
HCT116 cells in 
vitro and tumour 
xenografts in vivo 
PTT 
PTT induced 
cytotoxicity and tumour 
growth regression 
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Kelkar 2016 87 CT26 cells in vitro Dual wavelength PTT 
Synergistic dual 
wavelength PTT 
induced cytotoxicity 
Yang 2017 88 
HT29 cells in vitro 
and tumour 
xenografts in vivo 
PTT, PDT, tumour 
imaging and deliver 
SN38 
Synergistic PTT, PDT 
and chemo- induced 
cytotoxicity, tumour 
growth regression and 
confirmed tissue 
necrosis 
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Figure 1 
 
 
